Stromal Vascular Fraction for Treatment of Xerostomia

Summary

Prospective, single center, double armed, randomized treatment with observation only (standard of care) control group. Subjects receiving study treatment will have 6 months of study follow-up. Stromal vascular fraction (SVF), an adipose-derived tissue preparation, will be injected into salivary glands to determine safety and efficacy to restore saliva production in head and neck cancer patients with chronic xerostomia resulting from radiation therapy.

Timeline

Start

2018-11-01

Primary completion

2020-12-28

Completion

2020-12-31

Drugs

Indications